Table 1.
Baseline characteristics of patients in the study
| IAI | IVR | P-value | |
|---|---|---|---|
| No (eyes/patients) | 29/29 | 74/71 | |
| Female:male | 2:27 | 12:59 | 0.339 |
| Age (years) | 75±8 | 76±8 | 0.755 |
| logMAR BCVA | 0.292±0.309 | 0.299±0.271 | 0.721 |
| Lesion size (DA) | 3.5±2.6 | 4.1±2.5 | 0.334 |
| TFT (µm) | 249±85 | 267±115 | 0.634 |
| FRT (µm) | 110±72 | 120±68 | 0.198 |
| HSRD (µm) | 139±77 | 147±110 | 0.572 |
| SFCT (µm) | 242±93 | 239±95 | 0.866 |
| ELM (disrupted) | 1 (3.5%) | 5 (6.8%) | 1.000 |
| Ellipsoid zone (disrupted) | 8 (27.6%) | 23 (30.1%) | 0.814 |
| SRD | 27 (93.1%) | 62 (83.7%) | 0.339 |
| RPE elevation | 25 (86.1%) | 65 (87.4%) | 1.000 |
| IRF | 6 (20.6%) | 23 (31.0%) | 0.338 |
Note: Measured data is expressed as mean ± standard deviation.
Abbreviations: IAI, intravitreal aflibercept injection; IVR, intravitreal ranibizumab injection; logMar BCVA, the logarithm of the minimum angle of resolution best-corrected visual acuity; DA, disc area; TFT, total foveal thickness; FRT, foveal retinal thickness; HSRD, height of serous retinal detachment; SFCT, subfoveal choroidal thickness; ELM, external limiting membrane; SRD, serous retinal detachment; RPE, retinal pigment epithelium; IRF, intra retinal fluid.